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Epithelial±mesenchymal transformation is a critical event in the development of many organ systems including the heart.
Descriptive studies have implicated a number of factors in mediating this transformation, including transforming growth
factor b (TGFb). We now report that disruption of a TGFb signal transduction complex by antibodies directed against the
Type II TGFb receptor blocks both the endocardial cell activation and subsequent migration that constitute transformation
in the chick atrioventricular (AV) cushion. The Type II receptor was localized to both endothelial and endocardial cells
of the chick embryo. Incubation of AV cushion explants from Stage 14, 16, and 18 embryos with antibody resulted in a
blockade of AV endocardial cell transformation by greater than 50% as measured by mesenchyme formation. Similarly,
the appearance of procollagen Type I, a marker of endocardial cell transformation, was blocked. In addition, within 2 hr
after the incubation of activated Stage 18 explants with Type II antibody the rate of migration of transformed cells was
decreased by 50%. These data suggest that TGFb acts directly on AV cushion endocardial cells to stimulate epithelial±
mesenchymal transformation and that TGFb mediates at least two distinct components of AV cushion transformation,
activation and migration. q 1996 Academic Press, Inc.
INTRODUCTION that occurs in the genesis of a number of organ systems
including the kidney, lung, and eye (Hay, 1990, 1991). In
the heart this transformation is presumed to be dependentEarly in cardiac morphogenesis the heart consists of a
on factors secreted locally from the outer myocardial layersimple tubular structure made up of two concentric cylin-
that diffuse through the cardiac jelly. Since transformingders of epithelia separated by a gel-like matrix termed car-
growth factor b (TGFb) isoforms have been identi®ed indiac jelly. A critical step in cardiogenesis involves the trans-
cardiac tissue in vivo (Millan et al., 1991; Potts et al., 1992;formation of cells from speci®c regions of the inner endocar-
Dickson et al., 1993; Barnett et al., 1994), and TGFb1 ordial cell layer, including the atrioventricular (AV) cushion,
TGFb2 when combined with noninductive ventricularinto mesenchymal cells that invade the cardiac jelly and
myocardium has been demonstrated to induce AV cushionlater form the connective tissue of the valves and septa of
transformation in vitro (Potts and Runyan, 1989; Potts etthe adult heart (reviewed in Sadler, 1985). Many congenital
al., 1991; Nakijima et al., 1994), TGFb is likely to be aheart defects in humans are imperfections in valve or sep-
critical component of the signal that induces AV cushiontum formation that arise from abnormal AV cushion trans-
transformation.formation (Ferencz et al., 1985; Hoffman, 1990). The AV
Transforming growth factor b ligands are members of acushion is often cited as a classic example in developmental
superfamily of related growth factors that have been impli-biology of the epithelial ±mesenchymal cell transformation
cated in embryogenesis in both vertebrate and invertebrate
systems. These peptides have pleiotropic effects including
the regulation of cell growth, extracellular matrix produc-1 These authors contributed equally.
2 To whom reprint requests should be addressed. tion, and cell differentiation, all important regulators of cell
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position and identity during embryogenesis. Among the cell
surface proteins that TGFb binds in order to exert effects
on the cell, three have been shown by crosslinking to bind
ligand with picomolar af®nity. The Type I and Type II recep-
tors are serine/threonine kinases (Lin et al., 1992; Ebner et
al., 1993) while the Type III receptor has no known signaling
domain (Wang et al., 1991; Lopez-Casillas et al., 1991). Bio-
logical experiments in various cell types have suggested that
the Type II TGFb receptor is a critical and constitutive
component of all TGFb signaling complexes (Wrana et al.,
1994). To clarify the role of TGFb in cushion transformation
we chose to directly address the role of the Type II TGFb
receptor in AV cushion transformation. We have generated
polyclonal antibodies speci®c for the Type II receptor in
order to localize receptor protein during development and
determined that the Type II TGFb receptor is abundantly
expressed in endothelial cells throughout the developing
cardiovascular system. In addition, antibody to the Type II
TGFb receptor inhibits endocardial cell activation by myo-
cardium in vitro and, unexpectedly, markedly decreases the
migration rate of mesenchymal cells after transformation.
These data indicate that TGFb mediates multiple, distinct
aspects of AV cushion transformation and that TGFb signal-
ing persists throughout transformation and does not simply
constitute an on or off activation of AV cushion endothelial
cells.
FIG. 1. Map of Type II TGFb receptor fusion protein constructs
and Western analysis of Type II TGFb receptor expression in StageMATERIALS AND METHODS
18 embryos. A map of the Type II TGFb receptor cDNA is depicted
in A. The distinct regions of the molecule are indicated as follows:
Antibody preparation. Three constructs for the chick Type II extracellular ligand binding domain (white), the transmembrane
TGFb receptor (Barnett et al., 1994) were produced by PCR of por- spanning domain (hatched), and the consensus serine/threonine ki-
tions of the receptor cDNA and subcloned into pGEX-2T (Phar- nase domain (black). The regions of the extracellular domain used
macia) and the orientation and reading frame con®rmed by se- to generate the three fusion proteins constructs described under
quence analysis. Construct A encodes amino acids 27 through 85 Materials and Methods are indicated as A, B, and C. Construct A
(used to generate antibody g). Construct B begins at amino acid was used to generate antibody g, Construct B was used to generate
number 77 and ends with amino acid 148 (used to generate antibod- the antibodies z and d, and Construct C was used to generate anti-
ies z and d). Construct C encompasses both of the above regions body b. Depicted in B are Western blots using a representative
from amino acid 27 to 148 (used to generate antibody b) (Fig. 1A). antibody raised to each of one of the fusion proteins described
Upon induction each construct yielded the expected size GST fu- above. Each lane contains 30 mg of total protein harvested from
sion protein. Prior to injections, rabbits were bled and preimmune Stage 18 embryos. Primary antibody (designated g, z, andb) dilution
IgG was isolated with protein A±Sepharose. Rabbits were injected is at 1:100. Each sample was incubated without (0) or with (/) N-
at several subcutaneous and intramuscular sites with a total of 500 glycosidase F.
mg of fusion protein in Freund's adjuvant. Boosts were given at 4-
week intervals, and bleeds performed 14 days after a boost. Immune
antibody was prepared by the depletion and af®nity puri®cation of
immune sera (Harlow and Lane, 1988). Brie¯y, immune antibody
was prepared by depletion with total Escherischia coli cell lysate passing regions of the Type II receptor used as antigens speci®cally
inhibited antibody binding in these assays. These antibodies do notfrom bacteria containing the parental pGEX-2T vector. Following
induction, the resulting lysate was coupled to activated cyanogen cross-react with the extracellular domains of the chick Type I TGFb
receptors (Tsk-71/Alk2 or Alk5/R4 homologues) or the Type IIIbromide-coupled Sepharose. Sera were placed over the resulting
column and the ¯ow through tested for the loss of GST-binding by TGFb receptor.
WesternblotanalysisofTypeII TGFbreceptor antibody. West-Western blot (Towbin et al., 1979). Each serum was further af®nity
puri®ed using the corresponding GST-receptor fusion protein to ern analysis was performed on 30 mg of total protein per lane har-
vested from Stage 18 embryos. Each tissue is presented followingwhich the serum was raised. Protein concentrations of each prepa-
ration were determined and equal amounts of protein were used incubation of the homogenate alone (0) or with (/) N-glycosidase
F. For incubations with enzyme, 30 mg of protein in 30 ml of 0.5 Min each assay (Bradford, 1976). Antibodies speci®cally recognized
the chick Type II receptor overexpressed in COS cells by immuno- NaH2PO4 (pH 7.5), 0.5% SDS, 50 mM b-mercaptoethanol, and 50
mM EDTA was boiled for 5 min and cooled on ice for 5 min. Fifteenprecipitation, Western blotting, and immunohistochemistry, and
from chick tissue by the last two methods. Fusion proteins encom- microliters of 7.5% NP-40 and 0.5 U of N-glycosidase F (Boehringer
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Mannheim Biochemicals) were added and the solution volume ad-
justed to a total of 90 ml prior to incubation overnight at 377C. The
homogenate was separated on 8% SDS±PAGE and transferred to
nitrocellulose (Towbin et al., 1979). Primary antibody dilution was
at 1:100. Secondary antibody coupled to horseradish peroxidase was
at a dilution of 1:1000 and protein was visualized by chemolumi-
nescence (Renaissance, NEN-Dupont). For preadsorbtion undiluted
antibody was incubated with fusion protein at 201 protein concen-
tration overnight at 47C. This preadsorbed mixture was then diluted
to 1:100 ®nal antibody concentration.
Immunolocalization. For whole mount immunolocalization
(LeMotte et al., 1989), primary antibody concentration for both preim-
mune IgG and immune antibody was equalized at 120 mg/ml and
used at a 1:100 dilution. Protein was visualized using a 1:1000 dilution
of horseradish peroxidase-coupled anti-rabbit IgG and metal enhanced
3,3*-diaminobenzidine color substrate (gift from Pierce Chemical Co.).
Embryos were photographed on an Olympus RZH7 stereomicroscope.
For immunostaining sections, embryos were ®xed in Bouin's solution,
embedded, and cut in 5 mM sections. Primary antibody concentration
was a 1:100 dilution as described above. Protein was visualized using
a 1:1000 dilution of alkaline phosphatase-coupled anti-rabbit IgG
(Sigma) and NBT/BCIP color substrate (Promega). Sections were pho-
tographed using bright®eld optics on a Zeiss Axiophot. For pread-
sorbtion undiluted antibody was incubated with fusion protein at 201
protein concentration overnight at 47C. This preadsorbed mixture was
FIG. 6. Expression of Type II TGFb receptor by migrating mesen-then diluted to 1:100 ®nal antibody concentration.
chymal cells in vitro. Immunostaining of the Type II TGFb receptorCollagen gel assays. Atrioventricular cushion explants from
in a Stage 18 AV cushion explant by confocal microscopy is de-Stage 14, 16, and 18 (Hamburger and Hamilton, 1951) chick em-
picted. Migrating mesenchymal cells are seen expressing the Typebryos were harvested and placed in culture as described previously
II receptor. Differing intensity of staining re¯ects differences in the(Potts et al., 1992; Runyan and Markwald, 1983). Six hours after
depth of individual cells compared to the focal plane. Staining isplacing the explant, either preimmune IgG or immune antibody
visualized using an Indodicarbocyanine (Cy5) coupled secondary(10 mg/ml) was added, and the incubation continued for 16 to 18
antibody. Bar, 50 mm.hr. Activation and migration were scored on an inverted micro-
scope and the number of migrating mesenchymal cells was deter-
mined for each explant. To determine cell migration rate, explants
were videorecorded starting 45 min after the addition of antibody assays a concentration of 20 mg/ml fusion protein was preincubated
for a 2-hr period, and the migration distance of individual cells was with 10 mg/ml antibody. Only fusion proteins containing a se-
subjected to Bioquant analysis. Only cells that migrated within the quence to which a speci®c antibody was raised blocked activity in
plane of focus were used. For immunolocalization in collagen gel Western blotting and the transformation assay.
explants, the entire gel was ®xed in 4% PFA for 30 min. Gels were To determine the expression of procollagen Type I, explants were
incubated in a 1:1000 dilution of Type II receptor antibody for 48 placed on collagen gels for 6 hr, either preimmune or immune Type
hr at 47C. Speci®c staining was visualized using a Leica confocal II receptor antibody was added at 10 mg/ml, and the incubation
microscope after 24 hr of incubation in a 1:200 dilution of Indodi- continued for 48 hr with the addition of a fresh aliquot of antibody
carbocyanine (Cy5, Jackson Immunoresearch Laboratories) coupled at 24-hr intervals. Subsequently, the gel was harvested, ®xed, and
anti-rabbit IgG secondary antibody. incubated with the M-38 antibody to procollagen type I (Sinning
Fusion proteins to which the antibody was raised speci®cally et al., 1988). A ¯uorescence conjugated anti-rabbit antibody was
inhibited the effect of antibody addition to explants. For these ex- used to visualize protein by confocal microscopy.
periments, fusion proteins were prepared and puri®ed using gluta-
thione agarose beads and the resulting protein solution dialyzed RESULTS
against PBS overnight and stored at 47C until use. Protein concen-
In order to determine the speci®city of the antibodiestrations were determined and the ability of fusion proteins to block
antibody binding was determined by Western blotting. For in vitro generated to the Type II TGFb receptor we characterized
FIG. 2. Immunolocalization of the Type II TGFb receptor in Stage 18 embryos. Whole mount immunolocalization (A, B, C, D) and
immunostaining of sections (E, F, G, H) was performed by standard methods. A Stage 18 (A, B) embryo is depicted after incubation with
either preimmune or immune antibody (d), respectively. C and D depict higher power photographs focusing on endocardial expression in
the out¯ow tract (ot) and AV cushion (av). Speci®c staining of endothelial and endocardial cells was con®rmed by sectioning of whole
mount preparations as well as direct immunohistochemical localization of sections as depicted in E and F. Staining of the endocardial
cells extends throughout the endocardium including the atrial portion (a) and the trabeculations of the ventricle (v). G and H show a
higher power photograph of the cushion regions demonstrating endocardial staining (large arrows) and migrating mesenchymal cells (small
arrows). Bars in G and H are 25 mm.
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FIG. 3. Speci®city of whole mount immunolocalization and Western blot analysis of the Type II TGFb receptor in Stage 18 embryos.
Stage 18 embryos were used in whole mount immunolocalization and Western blot analysis (LeMotte et al., 1989; Towbin et al., 1979).
A depicts, from left to right, embryos incubated with primary antibody (d) preadsorbed with fusion protein construct A, preadsorbed with
fusion protein construct B that was used as an immunogen to generate the antibody, and no preadsorbtion. B depicts Western blots using
primary antibody (d) against 30 mg of protein per lane harvested from Stage 18 embryos. Each sample was incubated without (0) or with
(/) N-glycosidase F. Each pair of lanes, from left to right, represents preadsorption with fusion protein construct A, preadsorbed with
fusion protein construct B, and no preadsorption. A speci®c loss of both immunostaining and speci®c bands in Western blot analysis is
demonstrated following preabsorption with the appropriate fusion protein.
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the activity of each antibody in Western and immunoprecip- tained from Stage 14, 16, and 18 chick embryos and incu-
bated on three-dimensional, hydrated collagen gels for 6 hritation assays. Data from representative Western blots using
three antibodies generated to fusion constructs A, B, and C prior to the addition of either preimmune IgG or immune
antibody. In control explants, the endocardial cells form arespectively (Fig. 1A) are shown in Fig. 1B. Western analysis
demonstrates speci®c recognition of a single major band monolayer and, under the in¯uence of the myocardium,
undergo a speci®c activation, invasion of the matrix, and(Fig. 1B, ®rst lane of each pair labeled with ``0'') in Stage
18 total embryo protein. Some minor, smaller bands are subsequent migration that together constitute transforma-
tion. The activation step is characterized by a change frompresent and may represent differential glycosylation or pro-
teolytic fragments. The predicted size of the Type II receptor closely packed polygonal cells to a loose association of elon-
gated cells followed by the invasion of mesenchymal cellsbased on inferred amino acid sequence is 66 kDa while the
band noted on Western analysis is considerably larger (100 into the collagen matrix (Figs. 4A and 4C). The addition of
af®nity puri®ed Type II receptor antibody to explant cul-kDa), presumably due to glycosylation of the receptor. This
hypothesis was tested by incubating the tissue homogenates tures from each stage embryo resulted in the inhibition of
transformation as measured by mesenchyme formation. Inwith N-glycosidase F. This treatment resulted in a shift in
the molecular size of the band detected to approximately cultures incubated with preimmune IgG numerous mesen-
chymal cells are seen migrating into the collagen matrix75 kDa (Figure 1B, second lane of each pair labeled ``/'').
The band obtained following deglycosylation with N-gly- while activated endocardial cells are seen as elongated, sepa-
rated cells present on the surface of the matrix (Figs. 4A andcosidase F is consistently larger than that seen after in vitro
transcription/translation followed by immunoprecipitation 4C). These preimmune IgG-treated explants demonstrated
both a similar time course for transformation and a similar(data not shown) and the predicted size of the protein core
of the Type II receptor. This difference in apparent molecu- number of migrating cells when compared to explants cul-
tured with the addition of vehicle alone. In contrast, ex-lar size may re¯ect incomplete deglycosylation or other
posttranslational modi®cations. The expression of the plants treated with Type II receptor antibodies demon-
strated fewer migrating mesenchymal cells within the col-chick Type II TGFb receptor cDNA in COS cells followed
by Western analysis results in the appearance of a band lagen matrix and an abundance of densely packed,
polygonal- or cobblestone-shaped endocardial cells on thepattern similar to that seen in Fig. 1B. These data demon-
strate the speci®city of the antibody and the ability of the matrix surface (Figs. 4B and 4D). Data from a number of
explants harvested from Stage 14, 16, and 18 embryos dem-antibody to recognize native protein levels in tissue.
Whole mount immunolocalization of the Type II TGFb onstrate that mesenchyme formation was inhibited by at
least 50% for each of the antibodies tested (Fig. 5A). Thesereceptor in Stage 18 embryos demonstrated staining consis-
tent with localization to endocardial and endothelial cells data demonstrate no difference in the relative ability of each
antibody to inhibit mesenchyme formation at any stage ex-(Figs. 2A and 2B). Closer examination of the heart shows
receptor localization to the endocardial cells of the out¯ow amined. The cells that undergo transformation in the im-
mune antibody explants are presumably activated in situand AV cushion regions of the heart as well as the trabecu-
lations of the developing ventricle (Figs. 2C and 2D). Sec- by the myocardial signal prior to explant and are therefore
refractory to antibody treatment. Preincubation of speci®ctioning of these embryos or immunostaining performed di-
rectly on sections of Stage 18 chick embryos con®rmed this antibody with the fusion protein to which it was raised
blocked the inhibitory effects of antibody addition on trans-pattern of expression and localized cardiac staining to the
endocardial cells (Figs. 2E and 2F) and, to a lesser extent, formation while preincubation of antibody with fusion pro-
tein consisting of unrelated regions of the extracellular do-migrating mesenchymal cells delaminating from the endo-
cardial layer (Figs. 2G and 2H). The demonstration of recep- main of the Type II TGFb receptor had no effect on the
blockade of transformation by speci®c antibody. An anti-tor localization to the endocardial cells indicates that these
cells are competent to respond to the TGFb proposed to body to NCAM, a molecule known to be expressed on the
cell surface of these endocardial cells, does not alter activa-be secreted by the myocardium. In order to con®rm the
speci®city of the antibody staining, competing and non- tion or migration (Loeber and Runyan, 1990) suggesting that
the changes seen are attributable to Type II receptor inacti-competing GST-fusion proteins were used to preadsorb the
primary antibody. These experiments demonstrate that in vation and not nonspeci®c cell surface antibody binding. In
addition, 24 hr after explant incubation, procollagen Type Iboth whole mount immunoblotting and Western blot, pro-
tein generated from construct A had no effect on staining can be detected by immunohistochemistry in transforming
explants (Fig. 4E) (Sinning et al., 1988). The appearance ofor Western blotting (Figs. 3A and 3B). However, protein
generated from construct B that was used as the immunogen this phenotypic marker of cardiac mesenchymal cells is
blocked by Type II receptor antibodies (Fig. 4F). In addition,to raise the primary antibody blocks both immunolocaliza-
tion and Western blotting. procollagen Type I expression is known to be TGFb respon-
sive (Ritzenthaler et al., 1993). Therefore, the blockade ofTo determine the functional role of the Type II TGFb
receptor in AV cushion transformation we tested our poly- procollagen Type I expression is consistent with the disrup-
tion of TGFb signaling. This observation indicates disrup-clonal antibodies to the Type II receptor for neutralizing
activity in an in vitro model of cushion transformation tion of transformation by a measure that is not dependent
on morphology and strongly implies that the alterations in(Runyan and Markwald, 1983). Cushion explants were ob-
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cellular morphology and migration seen are the result of Type III TGFb receptors. Heteromeric complexes of the
Type I and Type II TGFb receptors that bind TGFb1 andthe blockade of a developmental program normally initiated
by TGFb acting directly on endocardial cells. TGFb3 with high af®nity have been implicated in mediat-
ing the effects of TGFb in mink lung epithelial cells (WranaFurther experiments using Stage 18 explants investigated
whether blockade of the Type II TGFb receptor had an effect et al., 1994). Bassing et al. (1994) reported the activation of
TGFb response elements via Type I receptor activation andon the migration rate of mesenchymal cells. Analysis of the
migration rate of transformed cells in the collagen matrix recently Wrana et al. (1994) have determined that the acti-
vation of TGFb response elements and growth arrest occursdemonstrated that antibody to the Type II TGFb receptor
signi®cantly decreased the migration rate of invading cells following the formation of a Type II±Type I receptor com-
plex and subsequent phosphorylation of the Type I receptor(Fig. 5B). This effect on the rate of migration was evident
within 2 hr after the addition of antibody and resulted in a by the Type II receptor. These data ®rmly establish a signal
transduction role for Type I±Type II heteromeric com-50% decrease in rate. In addition, immunostaining of ex-
plants demonstrates continued expression of the Type II plexes. The observation that more than one Type I-like re-
ceptor can interact with the Type II receptor suggests onereceptor by migrating mesenchymal cells (Fig. 6). These data
are consistent with TGFb not only inducing activation and possible mechanism for generating signaling diversity (Lin
and Moustakas, 1994). Recently, a Type I receptor isoforminvasion of endocardial cells but, in addition, supporting
the migration of transformed cells. This function of TGFb distinct from that seen in mink lung epithelial cells has
been postulated to play a role in epithelial±mesenchymalmay explain why TGFb ligand is expressed in the regions
of the AV cushion and out¯ow tract after the initiation transformation in cultured mammary epithelial cells, sup-
porting the hypothesis that signal diversity may be gener-of activation (Dickson et al., 1993; Barnett et al., 1994).
Persistent expression may be necessary to support mesen- ated by different Type I receptor isoforms (Miettinen et al.,
1994). In addition, the Type III TGFb receptor has beenchymal cell migration and extracellular matrix remodeling
in both the AV cushion and out¯ow tract. This role for demonstrated to form a functional complex with the Type
II receptor that binds TGFb2 with high af®nity (Wrana etTGFb is consistent with TGFb's known actions as a regula-
tor of extracellular matrix production and remodeling (Lin al., 1994; Lopez-Casillas et al., 1993; Henis et al., 1994)
while homomeric complexes of the Type II TGFb receptorand Moustakas, 1994). These data indicate that TGFb recep-
tor signaling is necessary to mediate at least two indepen- have also been identi®ed (Henis et al., 1994). Whether these
complexes have a signal transduction function is unknown.dent stages of AV cushion transformation, the activation
of AV endocardial cells and the migration of the resulting However, the differential expression of these various recep-
tor components is an attractive mechanism for the regula-mesenchymal cells.
tion of TGFb responsiveness.
Our observation that TGFb mediates multiple aspects of
transformation including activation and migration may helpDISCUSSION
to explain the complex pattern of ligand isoform expression in
the heart. Several ligand isoforms are present in the developingThe presence of the Type II TGFb receptor throughout the
vascular endothelium, including the entire endocardium, heart and may interact with distinct TGFb receptor com-
plexes to mediate one or more aspects of transformation. Forwhile only the AV cushion and out¯ow tract endocardium
respond to TGFb with transformation (Potts et al., 1992), example, TGFb3 has been shown to be critical for AV cushion
endocardial cell activation in the chicken, but is unable tosuggests the possibility that a speci®c TGFb receptor com-
plex may be localized to the cells of the AV cushion and support invasion and migration in collagen gels (Nakijima et
al., 1994). In addition, the high level of TGFb2 expression inout¯ow tract. Candidates for components of the putative
TGFb signaling complexes include both the Type I and the cardiac cushions that appears after activation and persists
FIG. 4. Effect of polyclonal antibodies to the Type II TGFb receptor on endocardial cell transformation in vitro. Stage 18 AV cushion
tissue explants were prepared as described under Materials and Methods. Representative cultures are shown here after 16±18 hr of
incubation. A depicts a transforming culture in the presence of 10 mg/ml preimmune antibody. Endocardial cells on the surface of the gel
are out of focus but show an irregular pattern consistent with activation and cell±cell separation. B depicts a similar culture incubated
with the Type II TGFb receptor antibody g, demonstrating a regular pattern of endocardial cells on the surface of the gel consistent with
quiescent endothelial cells. C shows an area of focus within the collagen gel containing numerous mesenchymal cells (arrows) in the
presence of 10 mg/ml of preimmune antibody. D shows a similar area of a second gel depicting a reduced number of mesenchymal cells
(arrows) following incubation with the Type II TGFb receptor antibody g. Although activation, invasion, and migration had been initiated
in these cultures prior to the addition of the antibodies, the addition of antibody blocked the continuation of these events. Shadows on
the right side of A±D are from the myocardial portion of the explant. E shows a higher magni®cation view of mesenchymal cells from
an explant incubated with preimmune antibody, cultured for 48 hr, and stained for procollagen Type I synthesis with the monoclonal
antibody M-38 (Sinning et al., 1988). Procollagen Type I, a phenotypic marker of cushion tissue (Sinning et al., 1988), was abundantly
expressed. F shows an explant identical to that seen in E incubated with the Type II TGFb receptor antibody g. Mesenchymal cells
(arrows) showed reduced or absent staining for procollagen Type I. Bar equals approximately 15 mm in each pair of ®gures.
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acting through distinct TGFb receptor complexes, may medi-
ate various aspects of AV cushion transformation. Regardless
of the ligand isoform mediating transformation our data dem-
onstrate that the Type II receptor is a necessary component
of each signaling complex that mediates both activation and
migration and that signals provided by one or more TGFb
ligands are critical to the transformation process. The develop-
ment of speci®c markers for distinct stages of transformation
is critical for our further understanding of the role of TGFb
and other factors in activation, invasion, and migration.
Our data demonstrating a role for the Type II TGFb recep-
tor in both activation and migration of endocardial cells
suggests that congenital heart defects due to AV cushion
imperfections may arise by a number of mechanisms in-
cluding the failure of TGFb to appropriately initiate AV
cushion endocardial cell activation or due to the altered
temporal and spatial expression of TGFb following activa-
tion that may result in incomplete or disorganized migra-
tion of mesenchymal cells. Further evaluation of the func-
tional TGFb signal transduction complex in AV cushion
endocardial cells will be critical for our understanding of
both AV cushion development and epithelial±mesenchy-
mal transformation in general.
FIG. 5. Effects of Type II TGFb receptor antibodies on transforma-
tion and migration. The effect of each of three af®nity puri®ed Type
II TGFb receptor polyclonal antibodies (designated g, z, and b) on the
transformation of AV cushion explants from Stages 14, 16, and 18 is ACKNOWLEDGMENTS
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